Navigation Links
Treating patients with psychiatric disorders for hepatitis C

People with severe mental illnesses are far more likely to be infected with Hepatitis C virus compared to the general population, however, they often do not get treatment for their liver disease because current antiviral therapies have known psychiatric side effects.

Against this epidemiological background, the article by Schaefer and colleagues, Hepatitis C treatment in psychiatric risk patients, represents an important study in the field, write Sanjeev Arora and Cynthia Geppert, in the December issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). Their editorial is also available online at Wiley Interscience (

It provides an even stronger empirical foundation for the findings of other less methodologically rigorous studies showing that patients with HCV and comorbid psychiatric and substance use disorders have comparable sustained viral responses (SVR) and rates of depression when treated with antiviral therapies, Arora and Geppert report.

While the National Institutes of Health once advised doctors against treating HCV-infected patients who continued to use illicit drugs, drink alcohol, or who had a psychiatric history, in 2002, the agency released a statement that said efforts should be made to increase the availability of the best current treatments to those patients.

Research has shown this approach to be feasible and effective, and it also has important implications for public health. Still, doctors have been slow to act on the recommendation.

Arora and Geppert applaud Shaefer et. als work with very difficult to treat patients and point out that the key to their success was the use of a multidisciplinary team. The patients in this study were carefully screened and monitored and received extensive education and counseling, they point out. They also praise the work because it assessed both depressive and psychotic symptoms and demonstrates that neither diagnosis adversely affected SVR or outcome. Instead, the study adds to the growing body of evidence that shows using anti-depressant agents prior to and during HCV treatment can lessen, or even prevent, depressive reactions.

While Arora and Geppert point out that the small sample size in Schaefer et. als study means that the conclusion that there is no difference in SVR between controls and patients with mental health diagnosis is stronger than the data can support, they praise the forward-thinking nature of the work.

The value of Schaefer et al.s work is precisely in contributing to the growing body of data that challenge hepatologists and mental health professionals to develop new medications and innovative programs that can further widen the door to admit these patients to HCV treatment, the authors conclude.


Contact: Amy Molnar

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
3. Treating diabetes during pregnancy can break link to childhood obesity
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Treating depression may improve recovery of heart rate variability following coronary syndromes
8. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
9. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
10. Stem cells show promise for treating Huntingtons disease
11. Treating obstructive sleep apnea, preventing heart attacks and strokes
Post Your Comments:
(Date:11/25/2015)... San Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... $15,000 in prizes were awarded to winners of the Create Real Impact awards. ... and creative expression to help stem the tide of distracted and reckless driving, the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a ... services to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus ... amount of time the doctor uses other traditional cutting tools, such as the scalpel ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... ... are national leaders when it comes to several aspects of orthopedic care. They ... joint replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ ... "Company") (NYSE: MR ), a ... medical devices worldwide, today announced that ... general meeting of shareholders at the ... Grand Century, 193 Prince Edward West Road, ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... heute bekanntgegeben, dass sie eine Lizenz für das Patent ... Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma ... von FUI AAP8 ins Leben gerufenen und von Edelris ... wurde FXR als ein Behandlungsziel für HBV identifiziert, und ...
Breaking Medicine Technology: